Silence Therapeutics plc (NASDAQ:SLN), a biotechnology company specializing in RNA therapeutics, stands at a crucial juncture in its development pipeline. With promising assets targeting significant ...

Silence Therapeutics (SLN) stock was initiated by Goldman Sachs with a Sell recommendation citing potential funding ...

Fintel reports that on February 11, 2025, Goldman Sachs initiated coverage of Silence Therapeutics plc - Depositary Receipt ( ...

Silence Therapeutics plc (NASDAQ:SLN – Get Free Report) has received an average recommendation of “Buy” from the six ratings ...

Goldman Sachs analyst Richard Law initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target Maximize Your ...

Goldman Sachs initiated coverage of Silence Therapeutics (SLN) with a Sell rating and $6 price target The company is developing siRNA ...

Silence Therapeutics has launched legal action alleging that late stage drugs from rivals Alnylam and The Medicines Company infringe its intellectual property. Silence, which specialises in ...

Stock analysts at The Goldman Sachs Group began coverage on shares of Silence Therapeutics (NASDAQ:SLN – Get Free Report) in a research report issued to clients and investors on Tuesday, Marketbeat ...

LONDON--(BUSINESS WIRE)--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies ...

7 analysts have expressed a variety of opinions on Silence Therapeutics (NASDAQ:SLN) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table provides ...

In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) stands against the other oversold global stocks. ‘There are decades where nothing happens, and there ...